Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110δ

被引:1
|
作者
Sawyer, C
Sturge, J
Bennett, DC
O'Hare, MJ
Allen, WE
Bain, J
Jones, GE
Vanhaesebroeck, B [1 ]
机构
[1] Univ Coll & Royal Free Med Sch Branch, Ludwig Inst Canc Res, Cell Signaling Grp, London W1W 7BS, England
[2] Kings Coll London, Randall Ctr Mol Mech Cell Funct, London SE1 1UL, England
[3] St George Hosp, Sch Med, Dept Anal & Dev Biol, London SW17 0RE, England
[4] Royal Free & Univ London Coll, Ludwig Inst Canc Res, Sch Med, Breast Canc Lab,Dept Surg, London W1W 7EJ, England
[5] Queens Univ Belfast, Inst Clin Sci, Dept Clin Biochem, Belfast BT12 6BJ, Antrim, North Ireland
[6] Univ Dundee, Sch Life Sci, Div Signal Transduct Therapy, Dundee DD1 5EH, Scotland
[7] UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Class IA phosphoinositide 3'-kinases (PI3Ks) regulate many cellular processes downstream of tyrosine kinases and Ras. Despite a clear implication of PI3K in cancer, little is known about the distribution of the different PI3K isoforms in malignant cells. We screened a large panel of tissues and cell lines for expression of class IA PI3Ks, and document a ubiquitous expression of the p110alpha and p110beta isoforms but a variable and more restricted tissue distribution of the p110delta isoform. Originally found in WBCs, p110delta was also detected in some nonhematopoietic cell types especially those of breast or melanocytic origin, both in the untransformed and transformed state. Isoform-specific neutralization of PI3K isoforms in breast cancer cell lines.(by PI3K antibody microinjection or a p110delta-selective pharmacological inhibitor) demonstrated that p110delta is the most important class IA PI3K in the regulation of epidermal growth factor-driven motility in vitro, controlling the directionality and, to a lesser extent, the speed of migration. In contrast, p110beta was required for the direction but not the speed of migration, whereas p110alpha did not impact on either of these parameters. These results show a nonredundant function of PI3K isoforms downstream of the epidermal growth factor receptor and indicate that the presence of p110delta may confer breast cancer cells with selective migratory capacities. The potential clinical implications of p110delta expression in non-WBC-derived tumors are discussed.
引用
收藏
页码:1667 / 1675
页数:9
相关论文
共 50 条
  • [21] Unique role for hepatic p110α phosphoinositide 3-kinase in metabolic homeostasis
    Sopasakis, Victoria Rotter
    Liu, Peter
    Suzuki, Ryo
    Kondo, Tatsuya
    Asano, Tomoichiro
    Roberts, Thomas M.
    Kahn, C. R.
    Zhao, Jean J.
    DIABETES, 2008, 57 : A375 - A375
  • [22] Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function
    So, Lomon
    Yea, Sung Su
    Oak, Jean S.
    Lu, Mengrou
    Manmadhan, Arun
    Ke, Qiao Han
    Janes, Matthew R.
    Kessler, Linda V.
    Kucharski, Jeff M.
    Li, Lian-Sheng
    Martin, Michael B.
    Ren, Pingda
    Jessen, Katti A.
    Liu, Yi
    Rommel, Christian
    Fruman, David A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (08) : 5718 - 5731
  • [23] Regulation of p110δ PI 3-Kinase Gene Expression
    Kok, Klaartje
    Nock, Gemma E.
    Verrall, Elizabeth A. G.
    Mitchell, Michael P.
    Hommes, Daan W.
    Peppelenbosch, Maikel P.
    Vanhaesebroeck, Bart
    PLOS ONE, 2009, 4 (04):
  • [24] Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer
    Gavgani, Fatemeh Mazloumi
    Arnesen, Victoria Smith
    Jacobsen, Rhian G.
    Krakstad, Camilla
    Hoivik, Erling A.
    Lewis, Aurelia E.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (12)
  • [25] Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase
    Carson, Jeffrey D.
    Van Aller, Glenn
    Lehr, Ruth
    Sinnamon, Robert H.
    Kirkpatrick, Robert B.
    Auger, Kurt R.
    Dhanak, Dashyant
    Copeland, Robert A.
    Gontarek, Richard R.
    Tummino, Peter J.
    Luo, Lusong
    BIOCHEMICAL JOURNAL, 2008, 409 (519-524) : 519 - 524
  • [26] Phosphoinositide 3-Kinase p110β Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development
    Ciraolo, Elisa
    Iezzi, Manuela
    Marone, Romina
    Marengo, Stefano
    Curcio, Claudia
    Costa, Carlotta
    Azzolino, Ornella
    Gonella, Cristiano
    Rubinetto, Cristina
    Wu, Haiyan
    Dastru, Walter
    Martin, Erica L.
    Silengo, Lorenzo
    Altruda, Fiorella
    Turco, Emilia
    Lanzetti, Letizia
    Musiani, Piero
    Rueckle, Thomas
    Rommel, Christian
    Backer, Jonathan M.
    Forni, Guido
    Wymann, Matthias P.
    Hirsch, Emilio
    SCIENCE SIGNALING, 2008, 1 (36)
  • [27] p110γ and p110δ phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells
    Tassi, Ilaria
    Cella, Marina
    Gilfillan, Susan
    Turnbull, Isaiah
    Diacovo, Thomas G.
    Penninger, Josef M.
    Colonna, Marco
    IMMUNITY, 2007, 27 (02) : 214 - 227
  • [28] Genetic or pharmaceutical blockade of p110δ phosphoinositide 3-kinase enhances IgE production
    Zhang, Ting-ting
    Okkenhaug, Klaus
    Nashed, Baher F.
    Puri, Kamal D.
    Knight, Zachary A.
    Shokat, Kevan M.
    Vanhaesebroeck, Bart
    Marshall, Aaron J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 122 (04) : 811 - 819
  • [29] Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation
    Yamaguchi, Hideki
    Fukami, Kiyoko
    Sakai, Ryuichi
    CANCER RESEARCH, 2011, 71
  • [30] Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation
    Yamaguchi, Hideki
    Yoshida, Shuhei
    Muroi, Emi
    Yoshida, Nachi
    Kawamura, Masahiro
    Kouchi, Zen
    Nakamura, Yoshikazu
    Sakai, Ryuichi
    Fukami, Kiyoko
    JOURNAL OF CELL BIOLOGY, 2011, 193 (07): : 1275 - 1288